SCHEMBL6791660

SCHEMBL6791660

COC(=O)c1ccc([N+](=O)[O-])cc1NC(=O)/C=C(/C)c1ccc2ccccc2c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TERT O14746 5/20 0.57
MEN1 O00255 5/20 0.50
KMT2A Q03164 5/20 0.50
SMN1; SMN2 Q16637 3/20 0.49
ALDH1A1 P00352 4/20 0.45
MAPT P10636 3/20 0.45
LMNA P02545 1/20 0.45
KDM4E B2RXH2 3/20 0.44
ALOX12 P18054 1/20 0.44
HPGD P15428 2/20 0.42
TP53 P04637 1/20 0.42
IKBKB O14920 1/20 0.42
PRMT5 O14744 1/20 0.42
WDR77 Q9BQA1 1/20 0.42
ATM Q13315 2/20 0.42
GAA P10253 2/20 0.41
GLA P06280 1/20 0.41
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
MAOA P21397 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6787247 0.92 TERT (0.59) TERTMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL6784799 0.90 TERT (0.71) TERTMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL6782397 0.86 TERT (0.64) TERTKMT2AALDH1A1MAPTLMNA
SCHEMBL6782114 0.85 SMN1; SMN2 (0.50) MEN1KMT2ASMN1; SMN2ALDH1A1MAPT
SCHEMBL6784696 0.84 TERT (0.67) TERTALDH1A1MAPTLMNAKDM4E
SCHEMBL6784219 0.84 TERT (0.78) TERTKMT2ASMN1; SMN2ALDH1A1LMNA
SCHEMBL6787759 0.84 TERT (0.71) TERTMEN1KMT2AALDH1A1MAPT
SCHEMBL6786975 0.83 TERT (0.61) TERTSMN1; SMN2ALDH1A1LMNAKDM4E
SCHEMBL6787843 0.83 TERT (0.61) TERTMEN1KMT2AALDH1A1MAPT
SCHEMBL6786390 0.82 TERT (0.60) TERTMEN1KMT2AALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6727250-B2 ADMINISTERING COMPOUNDS SUCH AS TRANS-3-(NAPHTH-2-YL)-BUT-2-ENOIC ACID-N-(2-CARBOXY-PHENYL)-AMIDE OR LIKE FOR THERAPY OF CONDITIONS ASSOCIATED WITH INCREASED TELOMERASE ACTIVITY, E.G. TUMOUR DISEASES BOEHRINGER INGELHEIM PHARMA KG (DE) 2004-04-27 US disclosed
EP-1261321-A2 CARBOXYLIC ACID AMIDES, MEDICAMENTS CONTAINING THESE COMPOUNDS AND THE USE AND PRODUCTION THEREOF Boehringer Ingelheim Pharma KG (DE) 2002-12-04 EP disclosed
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2002-07-25 US disclosed
US-6362210-B1 ANTITUMOR, ANTICANCER AGENT BOEHRINGER INGELHEIM PHARMA KG (DE) 2002-03-26 US disclosed
WO-2001007020-A2 CARBOXYLIC ACID AMIDES, MEDICAMENTS CONTAINING THESE COMPOUNDS AND THE USE AND PRODUCTION THEREOF BOEHRINGER INGELHEIM PHARMA KG (DE) 2001-02-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation TERT, NAT1, POT1 TERT 1/4885MEN1 896/4885KMT2A 490/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.